[Efficacy and tolerability of single-dose rosoxacin in the treatment of acute uncomplicated gonorrhea].
61 patients, male and female, with uncomplicated acute gonorrhea were given a single dose of 300 mg rosoxacin (2 capsules). 52 patients only completed clinical and laboratory controls. The drop-out rate for follow-up examinations was 14.8%. 98% of patients were cured. One patient failed to respond to treatment, and six had reinfection seven days later at follow-up control. Three of these were again treated with rosoxacin and cured. Among the side-effects, which were recorded in 24.4% of patients, dizziness was most prevalent (18.1%). Rosoxacin is particularly valuable in gonorrhea, given the single oral dose, the absence of resistance and the high percentage of efficacy.
D042462:4-Quinolones; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones
D042462:4-Quinolones; D000890:Anti-Infective Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin
Efficacité et tolérance de la rosoxacine à dose unique dans le traitement de la blennorragie aiguë non compliquée.